$5.13
1.18% yesterday
Nasdaq, Jul 01, 10:00 pm CET
ISIN
US0021201035
Symbol
ATYR
Sector
Industry

aTyr Pharma, Inc. Stock price

$5.13
+0.38 8.00% 1M
+1.51 41.71% 6M
+1.51 41.71% YTD
+3.57 228.85% 1Y
+2.28 80.00% 3Y
+0.83 19.30% 5Y
-232.87 97.84% 10Y
-204.17 97.55% 20Y
Nasdaq, Closing price Tue, Jul 01 2025
+0.06 1.18%
ISIN
US0021201035
Symbol
ATYR
Sector
Industry

Key metrics

Basic
Market capitalization
$456.6m
Enterprise Value
$381.5m
Net debt
positive
Cash
$76.4m
Shares outstanding
89.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 183.15
EV/Sales
- | 153.04
EV/FCF
negative
P/B
6.08
Financial Health
Equity Ratio
72.31%
Return on Equity
-91.44%
ROCE
-77.45%
ROIC
-
Debt/Equity
0.02
Financials (TTM | estimate)
Revenue
$0.0 | $2.5m
EBITDA
$-66.4m | $-74.9m
EBIT
$-67.1m
Net Income
$-63.4m | $-59.2m
Free Cash Flow
$-62.2m
Growth (TTM | estimate)
Revenue
-100.00% | 938.75%
EBITDA
-14.24% | -11.47%
EBIT
-14.09%
Net Income
-17.58% | 7.51%
Free Cash Flow
-7.26%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -3,005.17%
EBIT
-
Net
- | -2,374.99%
Free Cash Flow
-
More
EPS
$-0.73
FCF per Share
$-0.70
Short interest
18.71%
Employees
-
Rev per Employee
-
Show more

Is aTyr Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,952 stocks worldwide.

aTyr Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a aTyr Pharma, Inc. forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a aTyr Pharma, Inc. forecast:

Buy
94%
Hold
6%

Financial data from aTyr Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
9% 9%
-
- Research and Development Expense 53 53
14% 14%
-
-66 -66
14% 14%
-
- Depreciation and Amortization 0.70 0.70
1% 1%
-
EBIT (Operating Income) EBIT -67 -67
14% 14%
-
Net Profit -63 -63
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about aTyr Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

aTyr Pharma, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000 ® Index and broad market Russell 3000® Index, effective afte...
Neutral
GlobeNewsWire
28 days ago
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses.
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
More aTyr Pharma, Inc. News

Company Profile

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Sanjay Shukla
Founded 2005
Website www.atyrpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today